Effect of Timing of Monoclonal Antibody Therapy on the Time to Next Treatment and Response Rate in Heavily Pre-Treated Patients with Myeloma Who Separately Received Both Daratumumab and Elotuzumab-Based Regimens

Becnel Melody R.; Rubin M. Laura; Nair Ranjit; Manasanch Elisabet E.; Lee Hans C.; Patel Krina K.; Iyer Swaminathan P.; Thomas Sheeba K.; Weber Donna M.; Orlowski Robert Z.

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Effect of Timing of Monoclonal Antibody Therapy on the Time to Next Treatment and Response Rate in Heavily Pre-Treated Patients with Myeloma Who Separately Received Both Daratumumab and Elotuzumab-Based Regimens

【24h】

Effect of Timing of Monoclonal Antibody Therapy on the Time to Next Treatment and Response Rate in Heavily Pre-Treated Patients with Myeloma Who Separately Received Both Daratumumab and Elotuzumab-Based Regimens

机译：单克隆抗体治疗时序对骨髓瘤的大量预处理患者的下一次治疗和反应率的影响，分别接受了基于达拉穆克和基于Elotuzumab的方案

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共4页
作者
Becnel Melody R.; Rubin M. Laura; Nair Ranjit; Manasanch Elisabet E.; Lee Hans C.; Patel Krina K.; Iyer Swaminathan P.; Thomas Sheeba K.; Weber Donna M.; Orlowski Robert Z.;
展开▼
作者单位

Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Biostat Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Lymphoma &

Myeloma Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Lymphoma &

Myeloma Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Lymphoma &

Myeloma Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Lymphoma &

Myeloma Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Lymphoma &

Myeloma Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Lymphoma &

Myeloma Houston TX 77030 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Effect of Timing of Monoclonal Antibody Therapy on the Time to Next Treatment and Response Rate in Heavily Pre-Treated Patients with Myeloma Who Separately Received Both Daratumumab and Elotuzumab-Based Regimens [J] . Becnel Melody R., Rubin M. Laura, Nair Ranjit, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：单克隆抗体治疗时序对骨髓瘤的大量预处理患者的下一次治疗和反应率的影响，分别接受了基于达拉穆克和基于Elotuzumab的方案
2. Considerations for pre‐transfusion immunohaematology testing in patients receiving the anti‐CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma [J] . Quach Hang, Benson Simon, Haysom Helen, Internal medicine journal . 2018,第2期

机译：用于接受抗CD38单克隆抗体达拉汀治疗多发性骨髓瘤的患者患者预输血免疫中心病学检测的考虑
3. Considerations for pre‐transfusion immunohaematology testing in patients receiving the anti‐CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma [J] . Quach Hang, Benson Simon, Haysom Helen, Internal medicine journal . 2018,第Suppla2期

机译：用于接受抗CD38单克隆抗体达拉汀治疗多发性骨髓瘤的患者患者预输血免疫中心病学检测的考虑
4. A study of CD4-stratified timing of antiretroviral therapy among patients receiving integrated tuberculosis and HIV treatment in a highly resource-limited setting. [D] . Patel, Monita R. 2013

机译：在资源有限的情况下，对接受结核病和艾滋病毒综合治疗的患者进行CD4分层抗逆转录病毒治疗时机的研究。
5. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab [O] . Michael. S. van der Veer, Michel de Weers, Berris van Kessel, 2011

机译：迈向有效的骨髓瘤免疫治疗：通过来那度胺与人CD38单克隆抗体daratumumab的组合增强对骨髓瘤细胞的清除
6. Adjusted Comparison of Daratumumab Monotherapy Versus Real-World Historical Control Data From The Czech Republic in Heavily Pre-Treated and Highly Refractory Multiple Myeloma Patients [O] . J Diels, X Gatopoulou, H Besson, 2016

机译：在捷克共和国在捷克共和国对捷克共和国的实际历史控制数据的调整后比较，在大量预处理和高度难治多骨髓瘤患者中

Effect of Timing of Monoclonal Antibody Therapy on the Time to Next Treatment and Response Rate in Heavily Pre-Treated Patients with Myeloma Who Separately Received Both Daratumumab and Elotuzumab-Based Regimens

著录项

相似文献

相关主题

期刊订阅